Provided by Tiger Trade Technology Pte. Ltd.

X4 Pharmaceuticals Inc

3.56
-0.1000-2.73%
Post-market: 3.560.00000.00%19:55 EST
Volume:831.85K
Turnover:3.04M
Market Cap:311.27M
PE:-0.34
High:3.82
Open:3.70
Low:3.52
Close:3.66
52wk High:17.96
52wk Low:1.35
Shares:87.44M
Float Shares:69.55M
Volume Ratio:1.53
T/O Rate:1.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-10.5034
EPS(LYR):-5.5878
ROE:-156.87%
ROA:-33.54%
PB:5.05
PE(LYR):-0.64

Loading ...

X4 Pharmaceuticals to Join Guggenheim Emerging Outlook Biotech Summit

Reuters
·
Feb 03

BRIEF-X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule

Reuters
·
Feb 03

X4 Pharmaceuticals Grants Stock Options to New Employees Under Inducement Plan

Reuters
·
Feb 03

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Feb 03

X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) Shares May Have Run Too Fast Too Soon

Simply Wall St.
·
Dec 24, 2025

X4 Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Nov 10, 2025

X4 Pharmaceuticals to Join Guggenheim Healthcare Innovation Conference

Reuters
·
Nov 06, 2025

X4 Pharma Q3 net loss narrows to $29.8 mln

Reuters
·
Nov 05, 2025

X4 Pharmaceuticals Reports $240 Million Financing and Shifts Focus to Phase 3 Chronic Neutropenia Trial

Reuters
·
Nov 05, 2025

X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Nov 05, 2025

X4 Pharmaceuticals Raises $155.3 Million in Public Offering

Reuters
·
Oct 28, 2025

X4 Pharmaceuticals Executive Chairman Adam R. Craig Reports Acquisition of Common Shares

Reuters
·
Oct 28, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Cipher Mining, Kura, GrafTech

Reuters
·
Oct 24, 2025

X4 Pharmaceuticals Prices $135 Million Public Offering of Common Stock and Pre-Funded Warrants

Reuters
·
Oct 24, 2025

X4 Pharmaceuticals Inc - Prices Public Offering at $2.90 per Share

THOMSON REUTERS
·
Oct 24, 2025

X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering

THOMSON REUTERS
·
Oct 24, 2025

BRIEF-X4 Pharmaceuticals Announces Proposed Underwritten Public Offering

Reuters
·
Oct 24, 2025

X4 Pharmaceuticals Inc - Proceeds to Fund Phase 3 Development of Mavorixafor

THOMSON REUTERS
·
Oct 24, 2025

X4 Pharmaceuticals announces restructuring, 50% reduction in workforce

TIPRANKS
·
Sep 17, 2025

X4 Pharmaceuticals - John Volpone Appointed COO in Addition to Current Role as President

THOMSON REUTERS
·
Sep 17, 2025